Gilead Sciences (GILD) Stock Forecast & Price Target

$125.19 +0.14 (+0.11%)

Closing price 06/24/2026 03:59 PM Eastern

Extended Trading

$125.03 -0.16 (-0.13%)

As of 06/24/2026 07:52 PM Eastern

Compare

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 29 Analyst Ratings

Sell
0

Hold
4

Buy
25

Based on 29 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 4 have given a hold rating, and 25 have given a buy rating for GILD.

Consensus Price Target

$158.41
26.53% Upside

According to the 29 analysts' twelve-month price targets for Gilead Sciences, the average price target is $158.41. The highest price target for GILD is $180.00, while the lowest price target for GILD is $122.00. The average price target represents a forecasted upside of 26.53% from the current price of $125.19.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GILD Analyst Ratings Over Time

Type	Current Forecast 6/25/25 to 6/25/26	1 Month Ago 5/26/25 to 5/26/26	3 Months Ago 3/27/25 to 3/27/26	1 Year Ago 6/25/24 to 6/25/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	25 Buy rating(s)	25 Buy rating(s)	24 Buy rating(s)	15 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$158.41	$156.93	$157.62	$110.55
Forecasted Upside	26.53% Upside	17.35% Upside	17.40% Upside	4.36% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gilead Sciences Stock vs. The Competition

Type	Gilead Sciences	Medical Companies	Broader Market
Consensus Rating Score	2.86	2.29	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	26.53% Upside	817.13% Upside	15.50% Upside
News Sentiment Rating	Positive News See Recent GILD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/16/2026	Cantor Fitzgerald 5 of 5 stars	Carter Gould 4 of 5 stars	Reiterated Rating	Overweight	$155.00	+23.37%
6/8/2026	Royal Bank Of Canada 3 of 5 stars	Brian Abrahams 4 of 5 stars	Reiterated Rating	Sector Perform
5/28/2026	Weiss Ratings 5 of 5 stars		Downgrade	Buy (B) ➝ Buy (B-)
5/20/2026	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Okunewitch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$165.00	+26.44%
5/19/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$161.00 ➝ $150.00	+14.65%
5/11/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$170.00 ➝ $167.00	+25.18%
5/8/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target		$175.00 ➝ $168.00	+27.92%
5/8/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$148.00 ➝ $146.00	+11.17%
5/8/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$155.00 ➝ $157.00	+19.65%
4/17/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$125.00 ➝ $130.00	-5.41%
Stranded On The Flood Plains of History (Ad) The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar. Read Porter's full briefing and get the ticker names today
4/13/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$156.00 ➝ $165.00	+19.83%
3/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$180.00	+22.76%
2/23/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$170.00	+13.53%
2/20/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Equal Weight	$155.00	+2.57%
2/19/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$135.00 ➝ $165.00	+9.18%
2/18/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$140.00 ➝ $170.00	+11.30%
2/12/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$155.00 ➝ $170.00	+9.11%
2/11/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$160.00	+3.14%
2/11/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target	Buy	$162.00	+4.03%
2/11/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$128.00 ➝ $165.00	+5.91%
2/11/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$135.00 ➝ $155.00	-0.51%
2/11/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tyler Van Buren Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$145.00 ➝ $160.00	+2.70%
2/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$150.00 ➝ $165.00	+12.07%
2/11/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$150.00 ➝ $160.00	+8.67%
2/11/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louis Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$140.00 ➝ $177.00	+20.22%
1/26/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$145.00 ➝ $155.00	+12.54%
1/26/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$135.00 ➝ $150.00	+10.35%
12/10/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Hold	$110.00 ➝ $133.00	+11.43%
9/5/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Moderate Buy
2/13/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$108.00	+4.54%
2/12/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Catanzaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$105.00 ➝ $110.00	+6.33%
11/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$80.00 ➝ $95.00	-2.30%
8/9/2024	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$93.00	+39.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:53 AM ET.

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 22, 2026. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

The current stock price is around $132, which is significantly lower than its 52-week high of $157.29, indicating potential for price appreciation.
Gilead Sciences, Inc. recently reported strong quarterly earnings, with earnings per share (EPS) of $2.03, surpassing analyst expectations, which reflects the company's robust financial health.
The company has a solid net margin of approximately 31%, suggesting effective cost management and profitability, which can be attractive to investors looking for stable returns.
Gilead Sciences, Inc. has a dividend yield of about 2.6%, providing a steady income stream for investors, which is particularly appealing in a low-interest-rate environment.
Recent FDA acceptance of Gilead’s filing for a once-weekly oral HIV prevention medication could open new growth avenues, enhancing the company's product portfolio and market position.

Gilead Sciences
Bear Case

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

The company has set its fiscal year 2026 guidance for EPS between -1.050 and -0.650, indicating potential challenges in maintaining profitability in the near future.
Analysts project a negative EPS of -0.8 for the current fiscal year, which may raise concerns about the company's ability to generate earnings.
Despite a strong revenue increase of 4.4% year-over-year, the overall market sentiment may be cautious due to the competitive landscape in the biopharmaceutical sector.
The debt-to-equity ratio stands at 0.89, which, while manageable, suggests that the company is utilizing a significant amount of debt to finance its operations, potentially increasing financial risk.
Recent donations of remdesivir to support public health efforts, while positive for corporate image, may not have a direct financial impact, raising questions about the allocation of resources.

GILD Forecast - Frequently Asked Questions

According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $158.41, with a high forecast of $180.00 and a low forecast of $122.00.

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 4 hold ratings and 25 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GILD shares.

According to analysts, Gilead Sciences's stock has a predicted upside of 26.53% based on their 12-month stock forecasts.

Over the previous 90 days, Gilead Sciences's stock had 3 upgrades and 1 downgrade by analysts.

Gilead Sciences has been rated by research analysts at Cantor Fitzgerald, Citigroup, Daiwa Securities Group, Leerink Partners, Maxim Group, Morgan Stanley, Rothschild & Co Redburn, Royal Bank Of Canada, The Goldman Sachs Group, Truist Financial, and Weiss Ratings in the past 90 days.

Analysts like Gilead Sciences more than other "medical" companies. The consensus rating for Gilead Sciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how GILD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Gilead Sciences Recommendations

This page (NASDAQ:GILD) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Stock Forecast & Price Target